Dear Yvonne

Following your enquiry in relation to the ADLC scheme for the ADVIA series of instruments, I would like to take this opportunity to provide guidance in relation to running samples on the ADVIA 2120 and ADVIA 2120i Haematology Analysers.

These systems are FDA approved for the enumeration and reporting of circulating nucleated red blood cell counts (nRBCs) whilst performing the standard FBC & Differential test profile. However, if this parameter has been enabled in the system software, the analyser will report an inaccurate WBC differential result on ADLC samples, as a result of the material used to manufacture the survey sample.

Therefore, in order for the participants of the scheme to obtain accurate results for the ADLC samples, it is recommended that the nRBC method is temporarily disabled on those systems reporting these results, prior to analysis of the ADLC samples. In order to accomplish this, operators should follow the software steps detailed below:

Customise > System Setup > Morphology Flagging

The Morphology Flagging Configuration window contains a ‘Report NRBC Results’ check box that should be disabled when running ADLC samples.

Having disabled the 'Report NRBC Results' check box, operators should click on save and then follow the software steps below to return to routine operations:

Operations > Log On / Log Off

and then ensure that the correct Operator ID code is entered into the system prior to running samples.

An example of the window is shown below.
The entire process should be reversed following completion of the analysis of ADLC samples. Clearly, if laboratories are not reporting nRBCs routinely, there is no requirement to modify the software prior to running the ADLC samples.

It should be noted that the issues associated with the ADLC scheme and the accurate reporting of WBC differentials has no impact on the ability of the ADVIA 2120 and ADVIA 2120i Haematology Systems to report nRBCs counts for human samples, as specified in the method information supplied with the system.

I trust this information will provide sufficient information for scheme participants to provide accurate results for the ADLC scheme, but please do not hesitate to contact me should additional guidance be required.

Yours sincerely

Graham Gibbs
Clinical Marketing Manager, Haematology & Plasma Proteins